A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: An unusual presentation of a rare disease

American Journal of Surgical Pathology

Volumn 37, Issue 1, 2013, Pages 147-151

  Chen, Dong ^a   Bachanova, Veronika ^b   Ketterling, Rhett P ^a   Begna, Kebede H ^a   Hanson, Curtis A ^a   Viswanatha, David S ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

eosinophilia; myeloid sarcoma; PDGFRA

Indexed keywords

ANTINEOPLASTIC AGENT; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1 PDGFRA FUSION PROTEIN, HUMAN; FIP1L1 PROTEIN, HUMAN; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; IMATINIB; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; BONE MARROW CANCER; BONE MARROW CELL; CASE REPORT; GENE REARRANGEMENT; GENETICS; HUMAN; IMMUNOPHENOTYPING; MALE; METABOLISM; PATHOLOGY; REMISSION; SARCOMA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; BONE MARROW NEOPLASMS; GENE REARRANGEMENT; HUMANS; IMMUNOPHENOTYPING; MALE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REMISSION INDUCTION; SARCOMA; TREATMENT OUTCOME;

EID: 84871623818     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31826df00b     Document Type: Article

References (23)

1. Bain BJ, Gilliland DG, Horny H-P, et al. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC); 2008.
2. Rives S, Alcorta I, Toll T, et al. Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement. J Pediatr Hematol Oncol. 2005;27: 663-665.
3. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006;30:965-970.
4. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
5. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093-3096.
6. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21:1183-1188.
7. Huang Q, Snyder DS, Chu P, et al. PDGFRA rearrangement leading to hyper-eosinophilia, T-lymphoblastic lymphoma, myelo-proliferative neoplasm and precursor B-cell acute lymphoblastic leukemia. Leukemia. 2011;25:371-375.
8. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
9. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103:473-478.
10. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038-3045.
11. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 2004;104: 1931-1939.
12. Rotoli B, Catalano L, Galderisi M, et al. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hyper-eosinophilic syndrome. Leuk Lymphoma. 2004;45:2503-2507.
13. Tefferi A, Lasho TL, Brockman SR, et al. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica. 2004;89:871-873.
14. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia. 2005;19:792-798.
15. Pitini V, Sturniolo G, Cavallari V, et al. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. Br J Haematol. 2006;132:123.
16. Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 2002;11:1391-1397.
17. Walz C, Curtis C, Schnittger S, et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4) (q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer. 2006;45:950-956.
18. Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol. 2007;138:77-81.
19. Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 2006;20:827-832.
20. Buijs A, Bruin M. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia. Leukemia. 2007;21:1104-1108.
21. Rudzki Z, Giles L, Cross NC, et al. Myeloid neoplasm with rearrangement of PDGFRA, but with no significant eosinophilia: should we broaden the World Health Organization definition of the entity? Br J Haematol. 2012;156:558.
22. Valent P, Akin C, Metcalfe DD. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest. 2007;37:153-154.
23. Tsimberidou AM, Kantarjian HM, Estey E, et al. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003;17: 1100-1103.